Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 3 study of recombinant von Willebrand factor for severe hereditary von Willebrand disease
NL-OMON50545Phase 3Active, not recruiting
- Sponsor
- Baxalta
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of vonicog alfa and recombinant human coagulation factor VIII in von Willebrand disease (VWD), sponsored by Baxalta. Started Jul 2018; status: active, not recruiting.
02
Drugs
vonicog alfarecombinant human coagulation factor VIII
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON50545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50545.